III 

117TH CONGRESS 

2D SESSION S. RES. 614 

Designating July 20, 2022, as ‘‘Glioblastoma Awareness Day’’. 

IN THE SENATE OF THE UNITED STATES 

MAY 3, 2022 

Mr. GRAHAM (for himself, Ms. SINEMA, Mr. KELLY, Mr. COONS, Ms. WARREN, Mr. MARKEY, and Mr. SCOTT of South Carolina) submitted the following resolution; which was considered and agreed to 

RESOLUTION 

Designating July 20, 2022, as ‘‘Glioblastoma Awareness 

Day’’. 

Whereas approximately 13,460 new cases of glioblastoma will 

be diagnosed in the United States in 2022; 

Whereas glioblastoma is— 

(1) the most common malignant brain tumor, accounting for approximately 1⁄2 of all primary malignant 

brain tumors; and 

(2) the most aggressive, complex, difficult to treat, 

and deadly type of brain tumor; 

Whereas it is estimated that more than 10,000 individuals in 

the United States will succumb to glioblastoma each year; 


kjohnson on DSK79L0C42PROD with BILLS
2 

•SRES 614 ATS 

Whereas the 5-year survival rate for glioblastoma patients is 

only 6.8 percent, and the median length of survival for 

glioblastoma patients is only 8 months; 

Whereas glioblastoma is described as a disease that affects 

the ‘‘essence of self’’, as the treatment and removal of 

glioblastoma presents significant challenges due to the 

uniquely complex and fragile nature of the brain, the primary organ in the human body that controls not only 

cognitive ability, but also the actions of every organ and 

limb; 

Whereas patients and caregivers play a critical role in furthering research for glioblastoma; 

Whereas, relative to other types of cancers, brain cancer patients pay the second highest out-of-pocket costs for medical services in both the initial and end-of life phases of 

care; 

Whereas, although research advances may fuel the development of new treatments for glioblastoma, challenging obstacles to accelerating progress toward new treatments 

for glioblastoma remain, and there are no screening or 

early detection methods; 

Whereas, in 2021, the World Health Organization reclassified 

brain tumors and made significant changes to the molecular characteristics of a glioblastoma diagnosis, necessitating critical biomarker testing for patients suspected of 

having a possible glioblastoma; 

Whereas, although glioblastoma was first described in medical 

and scientific literature in the 1920s, and despite its devastating prognosis, only 4 drugs and 1 medical device 

have been approved by the Food and Drug Administration to treat glioblastoma since the 1920s, and the morVerDate Sep 11 2014 00:56 May 04, 2022 Jkt 029200 PO 00000 Frm 00002 Fmt 6652 Sfmt 6300 E:\BILLS\SR614.ATS SR614

kjohnson on DSK79L0C42PROD with BILLS
3 

•SRES 614 ATS 

tality rates associated with glioblastoma have changed little during the past 30 years; 

Whereas, in 2020, the National Cancer Institute established 

the Glioblastoma Therapeutics Network (referred to in 

this preamble as ‘‘GTN’’), as part of a national infrastructure to enhance and support the discovery and development of glioblastoma therapies available for multi-institutional GTN teams to drive therapeutic agents through 

pre-clinical studies and early-phase clinical trials, which 

are necessary to rapidly evaluate potential treatments to 

advance toward cures and improved quality of life; and 

Whereas there is a need for greater public awareness of glioblastoma, including awareness of both— 

(1) the urgent unmet medical needs of glioblastoma 

patients; and 

(2) the opportunities for research of, and treatment 

advances for, glioblastoma: Now, therefore, be it 

1 Resolved, That the Senate— 

2 (1) designates July 20, 2022, as ‘‘Glioblastoma 

3 Awareness Day’’; 

4 (2) encourages increased public awareness of 

5 glioblastoma; 

6 (3) honors the individuals who have died from 

7 glioblastoma, a devastating disease, or are currently 

8 living with it; 

9 (4) supports efforts to develop better treat10 ments for glioblastoma that will improve the long11 term prognosis for, and the quality of life of, individ12 uals diagnosed with the disease; 


kjohnson on DSK79L0C42PROD with BILLS
4 

•SRES 614 ATS 

1 (5) recognizes the importance of molecular bio2 marker testing to the diagnosis and treatment of 

3 glioblastoma; 

4 (6) expresses support for the individuals who 

5 are battling brain tumors, as well as the families, 

6 friends, and caregivers of those individuals; 

7 (7) urges a collaborative approach to brain 

8 tumor research among governmental, private, and 

9 nonprofit organizations, which is a promising means 

10 of advancing the understanding and treatment of 

11 glioblastoma; and 

12 (8) encourages continued investments in glio13 blastoma research and treatments, including through 

14 the Glioblastoma Therapeutics Network and other 

15 existing brain tumor research resources. 

Æ 


kjohnson on DSK79L0C42PROD with BILLS